Skip to main content

News

News

CCLG Little Princess Trust Project Grant Award (August 2021)

The group have been successful with an application for a 2 year grant for £175k from the CCLG Little Princess Trust for a project entitled 'Optimisation of the Treatment of Childhood Cancer Patient Populations through the use of Therapeutic Drug Monitoring'. This funding will allow continuation of an exciting programme of work which is positively impacting on the treatment of some of the most challenging childhood cancer patient groups. 

Bone Cancer Research Trusting Funding Award (July 2021)

We are delighted to announce that the group have been successful in applying for a Bone Cancer Research Trust (BCRT) research project grant. The funding of £150k is for a 2 year project entitled 'Optimising the Treatment of Teenagers and Young Adults with Ewing Sarcoma through an Increased Understanding of Clinical Pharmacology and Toxicity Biomarkers' and more information can be found on the BCRT website (https://www.bcrt.org.uk/research/current-research-projects/optimising-the-treatment-of-teenagers-and-young-adults-with-ewing-sarcoma).  

New drug formulation study published (May 2021)

This month has seen the publication of a manuscript from the group, reporting on the safety and clinical pharmacology of a novel oral liquid formulation of 13-cis retinoic acid in children with neuroblastoma. The study published in the journal Cancers (https://www.mdpi.com/2072-6694/13/8/1868), showed that the liquid formulation demonstrated superior bioavailability, increasing the likelihood of achieving therapeutic levels, and that safety and palatability also compared favourably to the capsule formulation. This new formulation is now available from Nova Laboratories and offers a clear positive impact for the treatment of high-risk neuroblastoma patients.

New publications in 2021 (April 2021)

The first quarter of 2021 has seen a number of manuscripts accepted for publication from the pharmacology group. A manuscript reporting on the development of a novel assay now being used in a Phase I clinical trial for the Bicycle Drug Conjugate BT1718, has been published in the journal Bioanalysis. Two important papers have also been published in the childhood cancer space, with a study investigating the pharmacokinetics and pharmacogenetics of cyclophosphamide in neonates and infants being published in Pharmaceuticals, along with a manuscript published in the British Journal of Clinical Pharmacology reporting on a decade of experience with therapeutic drug monitoring for the anticancer drug carboplatin. Finally, a collaborative study with the University of Perugia was published this month in the journal Leukemia. Further details of these new papers can be found in the ‘Our Outputs’ section of the website.

NIHR i4i Product Development Award (Feb 2021)

The project is titled, 'In-vitro diagnostic device development and validation, enabling point-of-care therapeutic drug monitoring for dose optimisation of anthracycline chemotherapy in a paediatric cancer setting'.

The £977,609 grant, in collaboration with colleagues at UCL, will be used to develop a novel device to measure drug levels in patients in order to control drug exposure. The aim is to avoid unnecessary side-effects for a group of drugs widely used in childhood cancer treatment.

Innovate UK Award (Jan 2021)

Phil Berry was awarded £75k from Innovate UK in September 2020, for a 3 year project entitled: Establishing a translational leader in precision medicine through knowledge transfer to develop point-of-care drug monitoring technologies.

Cancer Research UK Funding Award (2020)

The first platform study investigating the safety of DNA Damage response inhibitors in combination with curative intent doses of radiotherapy in stage II and III lung Cancer CONCORDE was funded by Cancer Research UK and will shortly announce its 1st pharmaceutical partner. It is led by Dr Alastair Greystoke and key biomarkers of cardiac toxicity will be analysed within the group.